Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cell line. Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cell line

We comprehensively analyzed the differentially expressed mRNAs (DEmRNAs) and lncRNAs (DElncRNAs) underlying the antitumor functions of BET inhibitors of human HCC cells using RNA sequencing (RNA-Seq). The pan-BET inhibitor ABBV-075 and BD2 specific inhibitor ABBV-744 attenuates the IFNγ-induced inflammatory response. In addition, BD2 inhibitors were predominantly effective in inflammatory response. Overall design: The gene expression profile was performed with control DMSO-treated HepG2 (Con), ABBV-075-treated HepG2 (ABBV-075 50 nM), ABBV-744-treated HepG2 (ABBV-744 50 nM), ABBV-744-treated HepG2 (ABBV-744 500 nM), IFNγ-treated HepG2 (IFNγ), IFNγ+ABBV-075-treated HepG2 (IFNγ+ABBV-075 50nM), IFNγ+ABBV-744-treated HepG2 (IFNγ+ABBV-744 50nM), IFNγ+ABBV-744-treated HepG2 (IFNγ+ABBV-744 500nM) . Samples were generated by deep sequencing, in triplicate, using Illumina 2500.